'The lower level of anticipated sales to Stryker in 2008 is clearly disappointing but we, as does Stryker, remain confident that the potential for Cormet in the world's largest orthopaedic market is substantial.'

This was 600p at one stage, started falling and then after the above statement. I recall that a broker downgraded target price to 300p.

Cheap at 160p?

position 22 on the Top % gainers list

should get even more attention tomorrow

from the news at 15:31 from moneyam 'Turning to the upside, Smith & Nephew was the top riser, up almost 3 percent, or 18 pence, at 636-1/2 after traders noted revived speculation that the orthopaedics firm could be a bid target for U.S. peer Zimmer Holdings Inc.'

CRG in the same sector, could be taken out on the cheap at say 300p - yes over double the current price! Remember an Analyst valued them at 300p if not a bid target! Cheap to say the least at the current SP IMHO

Please DYOR.

expecting an even larger rise than 7% tomorrow

from Ft.com 'Smith & Nephew was the day's main speculative feature on a revival of gossip that it could be a takeover target for Zimmer, its US orthopaedics peer.

Analysts saw some logic to the tale. S&N's hip resurfacing system would fill a gap for Zimmer, which last month delayed its rival product. S&N's latest results provided clarity about the possible cost of an investigation into its Plus division. Its shares rose 2.2 per cent to 632p, but bankers doubted contact had been made.'

Hello - Zimmer have a look at CRG, undervalued!

Read the morning paper round up...Zimmer bid mentioned in 5 of the newspapers, bodes well for CRG also IMHO.

No more posts from me, talking to myself!

alot more for these to rise, very early stages

BUY IMHO!

Corin Group H1 pretax profit up on higher revenues
AFX


LONDON (Thomson Financial) - Corin Group Plc., the UK orthopaedics manufacturer, said its first-half pretax profit rose 55 percent on a 63 percent rise in sales, reflecting the initial roll out of Cormet, its leading hip resurfacing product, in the United States.

'We remain confident of Cormet success in the U.S., although over a longer timeframe than previously anticipated,' Corin said.

It said it has made an encouraging start to the second half, with sales in line with the board's expectations.

For the six months to end-June, the pretax profit rose to 1.8 million pounds from 1.2 million pounds as sales increased to 22.9 million pounds from 14.0 million pounds.

level 2 looks weak, this looks like it will fall further and nothing positive for the remainder of 2008 from the results released, back down to 100p?

42% fall on news that US orthapedic sales are unlikely to materialise in the financial year. (despite favourable exchange-rates)
+Also some mention similar in UK.
This looks a tad careless to be in a business that is so product-dependent - What's most likley is that a competitor has a better product - anyone?
Currently 78p to buy...

And so it keeps on falling difficult to put a value on.

ZERO comes to mind!

I was going to say exactly the same thing.

However, we shouldn't upset existing shareholders you know.

why not?

Because they might start picking on the companies I've got where the sp has collapsed!

tell me, tell me ...... i need another target - lol!

shut up or I shall start talking about TAN to you!

;-)

don't care! ..... don't hold it any more

Though you bought at just over the quid mark.

When did you shift it?